Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and glucose tolerance. An open label trial.
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2018
Price : $35 *
At a glance
- Drugs Ciclosporin (Primary)
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- 23 Feb 2018 Status changed from recruiting to completed.
- 12 Oct 2012 New trial record